UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 695

Sortiert nach

Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6

International journal of molecular sciences, 2024-05, Vol.25 (10), p.5355

2024

Link zum Volltext

Verfügbarkeit prüfen

Pleural mesothelioma from fluoro-edenite exposure: PACAP and PAC1 receptor. A preliminary report

European journal of histochemistry, 2024-05, Vol.68 (2)

2024

Link zum Volltext

Verfügbarkeit prüfen

Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma?

Biotechnic & histochemistry, 2020-04, Vol.95 (3), p.171-175

2020

Link zum Volltext

Verfügbarkeit prüfen

The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma

Nuclear medicine communications, 2017-04, Vol.38 (4), p.312-318

2017

Link zum Volltext

Verfügbarkeit prüfen

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

Journal of thoracic oncology, 2017-09, Vol.12 (9), p.1421-1433

2017

Link zum Volltext

Verfügbarkeit prüfen

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

PloS one, 2015-03, Vol.10 (3), p.e0121071-e0121071

2015

Link zum Volltext

Verfügbarkeit prüfen

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays

Human pathology, 2019-05, Vol.87, p.11-17

2019

Link zum Volltext

Verfügbarkeit prüfen

A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis

Lung cancer (Amsterdam, Netherlands), 2018-11, Vol.125, p.198-204

2018

Link zum Volltext

Verfügbarkeit prüfen

The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma

Modern pathology, 2016-01, Vol.29 (1), p.14-24

2016

Link zum Volltext

Verfügbarkeit prüfen

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry

Lung cancer (Amsterdam, Netherlands), 2017-02, Vol.104, p.98-105

2017

Link zum Volltext

Verfügbarkeit prüfen

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma

Journal of thoracic oncology, 2017-05, Vol.12 (5), p.850-859

2017

Link zum Volltext

Verfügbarkeit prüfen

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study

Journal of clinical oncology, 2019-04, Vol.37 (10), p.790-798

2019

Link zum Volltext

Verfügbarkeit prüfen

BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma

Human pathology, 2015-11, Vol.46 (11), p.1670-1678

2015

Link zum Volltext

Verfügbarkeit prüfen

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma

Thorax, 2014-10, Vol.69 (10), p.895-902

2014

Link zum Volltext

Verfügbarkeit prüfen

Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma

PloS one, 2014-09, Vol.9 (9), p.e106742-e106742

2014

Link zum Volltext

Verfügbarkeit prüfen

Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study

Journal of thoracic oncology, 2015-03, Vol.10 (3), p.492-499

2015

Link zum Volltext

Verfügbarkeit prüfen

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas

Journal of thoracic oncology, 2017-04, Vol.12 (4), p.724-733

2017

Link zum Volltext

Verfügbarkeit prüfen

High mobility group box 1 mediates inflammatory responses in malignant peritoneal mesothelioma

International immunopharmacology, 2024-05, Vol.133, p.112039-112039, Article 112039

2024

Link zum Volltext

Verfügbarkeit prüfen

Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study

Human pathology, 2018-02, Vol.72, p.160-166

2018

Link zum Volltext

Verfügbarkeit prüfen

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

Annals of oncology, 2015-12, Vol.26 (12), p.2483-2490

2015

Link zum Volltext

Verfügbarkeit prüfen

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications

JNCI : Journal of the National Cancer Institute, 2018-10, Vol.110 (10), p.1102-1114

2018

Link zum Volltext

Verfügbarkeit prüfen

Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy

Proceedings of the National Academy of Sciences - PNAS, 2020-10, Vol.117 (41), p.25543-25552

2020

Link zum Volltext

Verfügbarkeit prüfen

Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis

American journal of clinical pathology, 2013-01, Vol.139 (1), p.39-46

2013

Link zum Volltext

Verfügbarkeit prüfen

Epithelial–mesenchymal transition in malignant mesothelioma

Modern pathology, 2012-01, Vol.25 (1), p.86-99

2012

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 695

Suche als RSS-Feed

Aktive Filter

PublikationsformNewsletter-Artikel

ThemaAged

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(637)
Mit Volltextzugriff
(627)

Publikationsform

Artikel
(694)
magazinearticle
(1)

Sprache

4 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Mesothelioma-Associated Fibroblasts Modulate the Response of Mesothelioma Patient-Derived Organoids to Chemotherapy via Interleukin-6

Pleural mesothelioma from fluoro-edenite exposure: PACAP and PAC1 receptor. A preliminary report

Can novel adipokines, asprosin and meteorin-like, be biomarkers for malignant mesothelioma?

The role of 18F-FDG-PET/ceCT in peritoneal mesothelioma

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma

Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays

A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis

The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma

Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: Comparison with 9p21 FISH and BAP1 immunohistochemistry

The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma

Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study

BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma

Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma

Targeted Next-Generation Sequencing of Cancer Genes in Advanced Stage Malignant Pleural Mesothelioma: A Retrospective Study

BAP1 Is Altered by Copy Number Loss, Mutation, and/or Loss of Protein Expression in More Than 70% of Malignant Peritoneal Mesotheliomas

High mobility group box 1 mediates inflammatory responses in malignant peritoneal mesothelioma

Aberrant Pax-8 expression in well-differentiated papillary mesothelioma and malignant mesothelioma of the peritoneum: a clinicopathologic study

A phase 1b clinical trial of the CD40-activating antibody CP-870,893 in combination with cisplatin and pemetrexed in malignant pleural mesothelioma

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications

Asbestos induces mesothelial cell transformation via HMGB1-driven autophagy

Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis

Epithelial–mesenchymal transition in malignant mesothelioma

Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort

Aktive Filter

Suchergebnisse filtern